

NORTH CENTRAL LONDON RED LIST - August 2021

This document is updated quarterly at the NCL Medicines Optimisation Committee.

It is published on the North Central London Joint Formulary Committee website (<https://www.ncl-mon.nhs.uk/documentation/moc/prescribing-policies/>).

It contains medicines that are on hospital formularies but owing to their speciality, safety or monitoring requirements, GPs should not be asked to continue the prescribing. The responsibility for prescribing these medicines should remain with the hospital trust consultant unless shared care has been agreed or in exceptional cases where transfer of treatment for an individual patient has been agreed with both the consultant and GP.

Further information on the background of the Red list and Shared Care can be found in Appendix 1 and 2 of the NCL Prescribing Guidance. If you have any queries on any of the information contained in this document, please contact your local NCL Medicines Management representative.

GPs should not be asked to take on the prescribing of any of the following drugs. It relates to all formulations unless a specific formulation is given.

***New additions are in bold and in red**

BNF Section	BNF Section Title	Generic Name
1.1.1	Antacids and Simeticone	Oxetacaine and antacid
1.2	Antispasmodics and other drugs altering gut motility	Propantheline Bromide (for post-operative hypersalivation/sialorrhoea in patients undergoing invasive head and neck surgery or injury)
1.3.3	Chelates and Complexes	Pepto-Bismol (as part of <i>H.pylori</i> eradication therapy), Sucralfate enema for radiation proctitis (not red listed for other indications)
1.4.3	Enkephalinase inhibitors	Telotristat
1.5.3	Drugs affecting the immune response	Vedolizumab
1.6	Laxatives	Plenvu [®] , Phospho-Soda[®]
1.7	Local preparations for anal and rectal disorders	Sucralfate enema (for radiation proctitis)
1.9.4	Pancreatin	Pancrex V Powder (for unblocking enteral tubes only)
2.1.2	Phosphodiesterase inhibitors	Enoximone, milrinone
2.3.2	Drugs for arrhythmias	Vernakalant, Mexiletine, Quinidine, Lidocaine (intravenous)
2.4	Beta-Adrenoceptor blocking drugs	Propranolol (For angiosarcoma or haemangioendothelioma use)
2.5.1	Vasodilator antihypertensive drugs	Ambrisentan bosentan, iloprost, sildenafil, tadalafil, treprostinil, macitentan, riociguat, hydralazine injection, sodium nitroprusside, selexipag
2.8.1	Parenteral (I.V) anticoagulants	All I.V. anticoagulants, low molecular weight heparin (Thromboprophylaxis in cancer patients whilst receiving chemotherapy only), Epoprostenol
2.8.2	Oral anticoagulants	Apixaban (Thromboprophylaxis in Multiple Myeloma patients initiated due to disease or concomitant thalidomide, lenalidomide or pomalidomide only)
2.9	Antiplatelet	Cangrelor
2.10.2	Fibrinolytics	Alteplase
2.12	Lipid-regulating drugs	Alirocumab, evolocumab
2.14	Unlicensed medicines/significant off-label use	Levosimendan
3.1.1	Adrenoceptor agonists	Salbutamol liquid for congenital myasthenic syndromes (not red listed for other indications)
3.2	Corticosteroids (respiratory)	Fluticasone dry powder inhaler (on red list for eosinophilic oesophagitis only), Budesonide nebulas (on red list for eosinophilic oesophagitis only)
3.3.3	Phosphodiesterase type-4 inhibitors	Roflumilast
3.4.2	Allergen immunotherapy	Grass Pollen Extract (Grazax [®]) for new patients, omalizumab, Mepolizumab
3.4.3	Allergic emergencies	C1-esterase inhibitor (Ruconest and Cinryze), Danazol and Oxandrolone (for hereditary angioedema), conestat alfa, icatibant, Lanadelumab
3.7	Mucolytics	Ivacaftor, mannitol, dornase alpha for new patients
3.11	Antifibrotics	Pirfenidone
4.1.1	Hypnotics	Sodium oxybate
4.1.2	Benzodiazepines	Lorazepam and Oxazepam for alcohol withdrawal
4.2.1	Antipsychotic drugs	Clozapine, Aripiprazole 9.75mg/1.3mL intramuscular injection
4.5.1	Anti-obesity drugs acting on the gastrointestinal tract	Liraglutide (Saxenda) for managing obesity
4.7.1	Non-opioid analgesics	Ziconotide

BNF Section	BNF Section Title	Generic Name
4.7.2	Opioid analgesics	Oral morphine solution for high-output stoma, Dropizol®
4.7.3	Neuropathic pain	Gabapentin (for multimodal analgesic regimen during the perioperative period in patients undergoing complex major neurosurgery)
4.7.4	Anti-migraine drugs	Fremanezumab, Galcanezumab, Erenumab
4.8	Anti-epileptic drugs	Cannabidiol oral solution 100mg/mL, Cenobamate (during NCL evaluation)
4.9.1	Dopaminergic drugs used in parkinsonism	Co-careldopa internal tube intestinal gel, apomorphine
4.9.3	Drugs used in essential tremor, chorea, tics and related disorders	Botulinum toxins type A and B , Tafamidis
5.1	Antibacterial drugs	All IV and inhaled antibacterials (or according to locally agreed primary care services – contact your local CCG for further information), Bedaquiline, Delamanid, ceftazidime-avibactam, combination metronidazole & neomycin for perioperative selective bowel decontamination, Rifaximin (for small intestinal bowel overgrowth in patients with systemic sclerosis) Linezolid is on the NCL Red List at all NCL Trusts <u>except RNOH</u> , who can share prescribing with a GP within the context of their MDT OPAT service
5.1.9	Antituberculosis drugs	Levofloxacin (for TB only), Terizidone
5.2	Antifungal drugs	Anidulafungin, caspofungin, micafungin, posaconazole, voriconazole
5.3	Antiviral drugs	Remdesivir
5.3.1	HIV infection	All antiretroviral drugs for treatment/prophylaxis of HIV infection; Adefovir, entecavir, interferon alpha, lamivudine, peginterferon alfa, ribavirin, telbivudine, tenofovir, boceprevir, telaprevir, Symtuza®
5.3.2.2	Cytomegalovirus	Cidofovir, foscarnet, ganciclovir, valganciclovir
5.3.3	Viral hepatitis including chronic Hepatitis C	All antivirals; glecaprevir/pibrentasvir (Maviret), sofosbuvir, velpatasvir, voxilaprevir (Vosevi) Adefovir, entecavir, interferon alpha, lamivudine, peginterferon alfa, ribavirin, telbivudine, tenofovir, boceprevir, sofosbuvir, telaprevir
5.3.4	Influenza	Zanamivir
5.3.5	Respiratory syncytial virus	Palivizumab, ribavirin
5.4	Antiprotozoal drugs	Pentamidine, atovaquone, meglumine antimoniate
5.5	Anthelmintics	Triclabendazole
6.1.2	Antidiabetic drugs	Empagliflozin for symptomatic neutropaenia secondary to GSD1b or G6PC3, Dapagliflozin or Sotagliflozin for type 1 diabetes
6.1.4	Treatment of hypoglycaemia	Diazoxide
6.2.1	Thyroid hormones	Tirosint® unit dose vials
6.3	Corticosteroids (endocrine)	Dexamethasone liquid (for moderate to severe wheeze & acute asthma in patients aged 1 month to 18 years)
6.5.1	Hypothalamic and anterior pituitary hormones and anti-oestrogens	Choriogonadotropin alfa, chorionic gonadotropin, clomifene (for IVF), corifollitropin alfa, Thyrotrophin alfa (Recombinant human thyroid stimulating hormone, rhTSH), Follitropin alfa and beta, human menopausal gonadotrophins, lutropin alfa, urofollitrophin, Pegvisomant
6.5.2	Posterior pituitary hormones	Terlipressin, Tolvaptan
6.6.1	Calcitonin and parathyroid hormone	Teriparatide, calcitonin
6.6.2	Bisphosphonates and other drugs affecting bone metabolism	Disodium pamidronate, ibandronic acid (injection), sodium clodronate (injection), zoledronic acid, ibandronic acid (for adjuvant treatment in breast cancer). Denosumab is on the Red List for any use of XGEVA®, and use of Prolia® only in osteoporotic male or female patients with renal impairment. Denosumab is also on the Red List for the treatment of Aneurysmal Bone Cysts in adults and paediatrics
6.7.2	Drugs affecting gonadotrophins	Cetrorelix, ganirelix, drugs for infertility (buserelin, goserelin, leuprorelin, nafarelin, triptorelin), Esmya® (ulipristal acetate for uterine fibroids)
6.7.3	Cushing's Syndrome	Ketoconazole tablets in metastatic prostate cancer and Cushing's syndrome
6.7.4	Somatomedins	Mecasermin
7.4.4	Bladder instillations and urological surgery	Parsons solution (Lidocaine-Heparin Bladder Instillation)
7.4.5	Drugs for Erectile Dysfunction	Drugs for ED (Alprostadil, avanafil, tadalafil, vardenafil, Viagra) unless for indications in Part XVIII B of the Drug Tariff- Drugs: Medicines and other substances that may be ordered only in certain circumstances. Papaverine hydrochloride (for vasospasm)

BNF Section	BNF Section Title	Generic Name
8.1	Cytotoxic Drugs	Oncology use of all I.V and oral cytotoxics
8.1.5	Malignant disease and Immunosuppression	Pembrolizumab, Everolimus, Ruxolitinib, Atezolizumab, Bevacizumab, Polatuzumab vedotin, Avelumab, Osimertinib, Nivolumab, Carfilzomib, Glasdegib, Venetoclax, Encorafenib, Cetuximab, Brigatinib, Pemigatinib, Ripretinib, Filgotinib, Acalabrutinib, Trastuzumab, Tepotinib, dasatinib, sotorasib, selpercatinib, avapritinib
8.2.2	Corticosteroids and other immunosuppressants	Basiliximab, daclizumab, sirolimus, tacrolimus (oral) for all new transplant patients (except liver transplant), mycophenolate for renal transplant patients, azathioprine for renal transplant patients, ciclosporin for renal transplant patients
8.2.3	Anti-lymphocyte monoclonal antibodies	Alemtuzumab, Rituximab, obinutuzumab, Blinatumomab, Isatuximab, Ofatumumab
8.2.4	Other immunomodulating drugs	Dimethyl fumarate, Peginterferon beta-1a, Teriflunomide, Aldesleukin, fingolimod, glatiramer, interferon alfa, interferon beta, lenalidomide, natalizumab, peginterferon alfa, thalidomide, olaparib, rucaparib, neratinib, selpercatinib, daratumumab, Siponimod, Belantamab mafodotin, Niraparib
8.3.4.2	Anti-androgens	Darolutamide for non-metastatic prostate cancer, Degarelix
8.3.4.3	Somatostatin analogues	Lanreotide, octreotide
8.3.4	Hormone Antagonists	Abiraterone, fulvestrant, Letrozole (for ovulation induction only), Enzalutamide, Apalutamide
9.1.1.1	Oral iron	Ferric maltol (Feraccru)
9.1.1.2	Parenteral iron	Ferric carboxymaltose (Ferinject®)
9.1.3	Drugs used in hypoplastic, haemolytic, and renal anaemias	Desferrioxamine (children and adults), deferasirox, deferiprone, erythropoietin, darbepoetin alfa, pegzerepoetin alpha, eculizumab, ravulizumab
9.1.4	Drugs used in platelet disorders	Anagrelide, eltrombopag, romiplostim, lusutrombopag, avatrombopag, caplacizumab
9.1.6	Drugs used in neutropenia	Filgrastim, lenograstim, molgramostim, pegfilgrastim
9.2.1.1	Potassium removal	Sodium zirconium cyclosilicate (Lokelma®), Patiromer (Veltassa®)
9.5.1.2	Hypercalcaemia and hypercalciuria	Cinacalcet
9.6.7	Multivitamin preparations	Forceval (for refeeding syndrome)
9.8.1	Drugs used in metabolic disorders	Agalsidase alfa and beta, betaine, carnitine, carglumic acid, eliglustat galsulfase, human hemin, idursulfase, imiglucerase, laronidase, mercaptamine, miglustat, nitisinone, penicillamine, sapropterin, sodium phenylbutyrate, glycerol phenylbutyrate
10.0	Musculoskeletal system	Abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab including dose escalation, methotrexate injections, tocilizumab, tofacitinib, apremilast, migalastat, Sarilumab
10.1.1	Non-Steroidal Anti-Inflammatory Drugs	Indometacin (for tocolytic therapy only)
10.1.2	Corticosteroids	Triamcinolone Acetonide (for oral mucosal inflammatory disease)
10.1.3	Rheumatic Disease Suppressant Drugs	anakinra, baricitinib, upadacitinib, secukinumab
10.2.1	Neuromuscular Disorders	Amifampridine phosphate, fampridine, Risdiplam
10.2.2	Skeletal muscle relaxants	Intrathecal baclofen
11.3.1	Eye - Antibacterials	Chlorhexidine 0.05% eye drops
11.4.1	Macular Oedema	Dexamethasone intravitreal implant (Ozurdex®), fluocinolone acetonide intravitreal implant
11.8.2	Ocular diagnostic and peri-operative preparations and photodynamic treatment	Aflibercept, bevacizumab (unlicensed ophthalmic indication), pegaptanib, ranibizumab, verteporfin, brolucizumab
13.8	Skin - Sunscreens and Camouflagers	Ameluz, Metvix
13.5.1	Preparations for eczema	Alitretinoin, Dupilumab
13.5.2	Preparations for psoriasis	Acitretin
13.5.3	Drugs affecting the immune response	Ustekinumab, efalizumab, etanercept, adalimumab, risankizumab, guselkumab, ixekizumab, abrocitinib
13.6.2	Oral preparations for acne	Isotretinoin
14.4	Vaccines and Antisera	Gardasil (for MSM under HIV/GUM clinics)
14.5	Immunoglobulins	Intravenous and sub cutaneous immunoglobulin
15.1	General anaesthesia	Hyperbaric Prilocaine 2%, Dexmedetomidine, Ketamine, Prilocaine 1%
15.1.2	Inhalational anaesthetics	Methoxyflurane
15.2	Local anaesthesia	Ropivacaine injection, Chloroprocaine, LAT gel, lidocaine 1% PF (when used for neonatal seizures), Levobupivacaine 0.125%, Bupivacaine 0.125%

BNF Section	BNF Section Title	Generic Name
	Miscellaneous	Artiss fibrin sealant, Floseal, Silver Diamine Fluoride, Idebenone (for duchenne muscular dystrophy), Patisiran (ATTR amyloidosis), Magnesium Lactate SR tablets (for renal tubule disorders), Ferric subsulphate (Monsels® solution), Dichlorphenamide, Intrathecal Fluorescein, Primovist, MultiHance, Indocyanine green +/- 99mTc-nanocolloid, Metronidazole 10% ointment (Ortem), Polatuzumab vedotin, 24% sucrose solution, Burosumab, Pentosan polysulfate sodium, Citric acid solution via nebuliser for cough-reflex testing, 5-Fluorouracil eye drops, Gadoxetate (Primovist®) Liver specific contrast agent, Insulin eye drops, human fibrinogen (Tisseel), besilesomab, lumasiran, Tecartus cells dispersion for infusion